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ABSTRACT
Background: Breast cancer (BC) is one of the most common invasive types of cancer among
women, with important consequences on both physical and psychological functioning.
Patients with BC have a great risk of developing posttraumatic stress disorder (PTSD), but
few studies have evaluated the efficacy of psychological interventions to treat it.
Furthermore, no neuroimaging studies have evaluated the neurobiological effects of psy-
chotherapeutic treatment for BC-related PTSD.
Objective: The study aimed to evaluate the efficacy of Eye Movement Desensitization and
Reprocessing therapy (EMDR) as compared to Treatment as Usual (TAU) in BC patients with
PTSD, identifying by electroencephalography (EEG) the neurophysiological changes under-
lying treatments effect and their correlation with clinical symptoms.
Method: Thirty patients with BC and PTSD diagnosis were included, receiving either EMDR
(n = 15) or TAU (n = 15). Patients were assessed before and after treatments with clinical
questionnaires and EEG. The proportion of patients who no longer meet criteria for PTSD
after the intervention and changes in clinical scores, both between and within groups, were
evaluated. Two-sample permutation t-tests among EEG channels were performed to inves-
tigate differences in power spectral density between groups. Pearson correlation analysis
was carried out between power bands and clinical scores.
Results: At post-treatment, all patients treated with EMDR no longer met criteria for PTSD,
while all patients treated with TAU maintained the diagnosis. A significant decrease in
depressive symptoms was found only in the EMDR group, while anxiety remained stable
in all patients. EEG results corroborated these findings, showing significant differences in
delta and theta bands in left angular and right fusiform gyri only in the EMDR group.
Conclusions: It is essential to detect PTSD symptoms in patients with BC, in order to offer
proper interventions. The efficacy of EMDR therapy in reducing cancer-related PTSD is
supported by both clinical and neurobiological findings.
Características neurobiológicas y respuesta a tratamiento con
desensibilización y reprocesamiento con movimientos oculares del
trastorno de estrés postraumático en pacientes con cáncer de mama
Antecedentes: El cáncer de mama (CM) es uno de los tipos de cáncer invasivo más comunes
entre las mujeres, con importantes consecuencias tanto en el funcionamiento físico como
psicológico. Los pacientes con CM tienen un gran riesgo de desarrollar trastorno de estrés
postraumático (TEPT), pero solo unos pocos estudios han evaluado la eficacia de las inter-
venciones psicológicas para tratarlo. Adicionalmente, ningún estudio de neuroimagen ha
evaluado los efectos neurobiológicos del tratamiento psicoterapéutico para el TEPT relacio-
nado con CM.
Objetivo: el estudio buscó evaluar la eficacia de la terapia de desensibilización y reproce-
samiento con movimientos oculares (EMDR) en comparación con el tratamiento habitual
(TAU) en pacientes con TEPT en CM, identificando también mediante EEG los cambios
neurofisiológicos que subyacen al efecto de los tratamientos y su correlación con los
síntomas clínicos.
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diagnosis in our sample of
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was 8.1%.
• EMDR was significantly
superior to TAU in reducing
PTSD and associated
depressive symptoms.
• Clinical improvement
following EMDR was
associated with an increase
in neuronal synchronization
in left angular and in right
fusiform gyri.
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Método: se incluyeron treinta pacientes con diagnóstico de CM y TEPT, recibiendo EMDR (n
= 15) o TAU (n = 15). Los pacientes fueron evaluados antes y después de los tratamientos
con cuestionarios clínicos y electroencefalografía (EEG). Se evaluó la proporción de
pacientes que dejaron de cumplir con los criterios para trastorno de estrés postraumático
después de la intervención y los cambios en las puntuaciones clínicas, tanto al interior como
entre los grupos. Se realizaron pruebas t de permutación de dos muestras entre canales EEG
para investigar las diferencias en la Densidad del Espectro de Potencia entre los grupos. Se
realizó un análisis de correlación de Pearson entre bandas de potencia y puntuaciones
clínicas.
Resultados: En el postratamiento, todos los pacientes tratados con EMDR ya no cumplían
con los criterios para TEPT, mientras que todos los pacientes tratados con TAU mantuvieron
el diagnóstico. Se encontró una disminución significativa de síntomas depresivos solo en el
grupo EMDR, mientras que la ansiedad se mantuvo estable en todos los pacientes. Los
resultados del EEG corroboraron estos hallazgos, mostrando diferencias significativas en las
bandas delta y theta en los giros angular izquierdo y fusiforme derecho solo en el grupo
EMDR.
Conclusiones: es esencial detectar los síntomas de TEPT también en pacientes con CM para
poder ofrecer intervenciones adecuadas. La eficacia de la terapia EMDR en reducir el
trastorno de estrés postraumático relacionado con el cáncer es apoyado tanto por los
hallazgos clínicos como neurobiológicos.
乳腺癌患者创伤后应激障碍的神经生物学特征及其对眼动脱敏和再加工
疗法的反应
背景：乳腺癌（BC）是女性中最常见的侵袭性癌症之一，对身心功能有重要影响。
BC患者发生创伤后应激障碍（PTSD）的风险很大，但只有少数研究评估了心理干预对其
治疗效果。此外，也没有神经影像学研究评估心理治疗对BC相关PTSD的神经生物学效
应。
目的：本研究旨在评估眼动脱敏和再加工疗法（EMDR）与普通治疗组（TAU）相比对BC
患者PTSD的疗效，同时通过EEG确定治疗效果的神经生理学变化及其与临床症状的相关
性。
方法：纳入30例同时患BC和PTSD的患者，接受EMDR（n = 15）或TAU（n = 15）。通过临
床问卷和脑电图（EEG）对患者进行治疗前和治疗后的评估。评估干预后不再符合PTSD标
准的患者比例以及组间和组内临床评分的变化。进行EEG通道之间的双样本置换t检验以
研究组间功率谱密度的差异。在功率带和临床评分之间进行Pearson相关分析。
结果：在治疗后，所有接受EMDR治疗的患者均不再符合PTSD标准，而所有接受TAU治疗
的患者均维持诊断。仅在EMDR组中发现抑郁症状显著减少，而在所有患者中焦虑保持稳
定。 EEG结果证实了这些发现，仅显示了EMDR组中左角和右侧梭形回旋区的δ和θ带的显
著差异。
结论：为了提供适当的干预措施，在BC患者中检测PTSD症状至关重要。临床和神经生物
学研究结果支持EMDR治疗在减少癌症相关PTSD方面的功效。
1. Introduction
Affecting over 1.5 million women each year, breast
cancer (BC) is one of the most invasive types of
cancer, also causing the greatest number of cancer-
related deaths (WHO, 2018). BC diagnosis and sub-
sequent treatment is an highly stressful condition,
with devastating effects on patient’s psychological
functioning and quality of life in addition to physical
suffering. For some patients this experience is decisi-
vely traumatic, with psychological consequences that
might result in posttraumatic stress disorder (PTSD;
Parikh et al., 2015).
PTSD is a mental disorder occurring after expo-
sure to life threatening episodes (criterion A) and is
characterized by: intense reliving of the traumatic
event through intrusive memories and nightmares
(criterion B); avoidance of reminders of the event
(criterion C); negative alterations in cognitions and
mood (criterion D); hypervigilance toward potential
threats in the environment (criterion E); and in some
cases persistent or recurrent depersonalization symp-
toms (American Psychiatric Association, 2013).
The publication of DSM-IV-TR (American
Psychiatric Association, 2000), explicitly including life-
threatening illness as a stressor that could elicit PTSD,
has stimulated investigations of posttraumatic sequelae
in cancer, myocardial infarction, intensive care treat-
ment, HIV and other medical conditions (Swartzman,
Booth, Munro, & Sani, 2017; Tedstone & Tarrier, 2003).
Several studies showed that 5–35% of patients with
cancer might suffer from posttraumatic symptoms
(Kangas, Henry, & Bryant, 2002) and that prevalence
of cancer-related PTSD is about 6% (Abbey, Thompson,
Hickish, & Heathcote, 2015). A recent meta-analysis
(Swartzman et al., 2017) showed that patients with
cancer are at increased risk of PTSD compared to
controls with no history of cancer while prevalence of
BC-related PTSD is 3–19% (Andrykowski, Cordova,
McGrath, Sloan, & Kenady, 2000).
In cancer patients, posttraumatic symptoms are
displayed as constant worries, fears of recurrence,
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nightmares about the illness or treatments, and a
sense of shortened future. Intrusive symptoms are
the preeminent ones, with a prevalence of 11–45%
(Matsuoka, Nagamine, & Uchitomi, 2006; Whitaker,
Brewin, & Watson, 2008).
DSM-5 PTSD diagnostic criteria (American
Psychiatric Association, 2013) advanced a debate
about the appropriateness of applying the concept
of PTSD to medical conditions such as cancer
(Cordova, Riba, & Spiegel, 2017; Kangas, 2013). To
date, no studies have used such criteria for assessing
PTSD among patients with cancer, calling for inves-
tigations exploring the features of PTSD in patients
with cancer and their response to psychotherapies.
In recent years, neuroimaging has disclosed the
neurobiological correlates of psychological and psy-
chiatric disorders. As regards PTSD, several studies
have shown the involvement of amygdala, medial
prefrontal Cortex (mPFC), anterior cingulate cortex
(ACC) and hippocampus (Patel, Spreng, Shin, &
Girard, 2012; Sherin & Nemeroff, 2011), being a
relative decreased mPFC activity and a parallel
increased amygdala activation the neurobiological
core of the disorder. These brain regions are also
implicated in cancer-related PTSD (Carletto &
Pagani, 2016), suggesting that effective treatments
for ‘typical’ PTSD can be effective also in cancer-
related PTSD.
Neuroimaging has also disclosed neurobiological
changes associated with the outcome of evidence-
based psychotherapeutic PTSD treatments, such as
Trauma Focused-Cognitive Behavioural Therapy
(TF-CBT) and Eye Movement Desensitization and
Reprocessing therapy (EMDR) (Malejko, Abler,
Plener, & Straub, 2017; Pagani, Högberg, Fernandez,
& Siracusano, 2013). The latter was found effective in
promoting a post-treatment reversal of prefrontal and
limbic alterations associated with long-lasting clinical
improvements (Högberg et al., 2008; Pagani et al.,
2012).
Few studies have shown that TF-CBT and EMDR
are effective in reducing PTSD symptoms in patients
with cancer (DuHamel et al., 2010; Jarero et al., 2015;
Kangas, Milross, Taylor, & Bryant, 2013). In a direct
comparison, EMDR was found to be significantly
more effective than TF-CBT in reducing PTSD symp-
toms (Capezzani et al., 2013).
EMDR is a trauma-focused psychotherapy using
alternate bilateral stimulation (eye movements, tactile
or audio) that seems to promote the reprocessing of
dysfunctionally-stored information related to the
traumatic event (Jeffries & Davis, 2013; Pagani,
Amann, Landin-Romero, & Carletto, 2017). It has
also been suggested to contribute to a better psycho-
logical adjustment to the disease in patients with
cancer (Faretta & Civilotti, 2016; Lantheaume, 2018;
Murray, 2016). Moreover, a specific EMDR therapy
protocol for patients with cancer has been recently
published (Faretta & Borsato, 2016), calling to com-
pare its effectiveness with a supportive psychological
intervention usually delivered in psycho-oncological
settings, aiming at informing clinicians about best
therapeutic options.
In the recent past, electroencephalography (EEG),
thanks to its optimal temporal resolution and directly
measuring neuronal activity, has emerged as a com-
plementary technique compared to the neuroimaging
techniques to deepen the comprehension of the
mechanisms underlying psychotherapies efficacy
(Pagani et al., 2012). Moreover, EEG features corre-
lating with psychological questionnaires might be
used as biomarkers to objectively test non-invasively
the efficacy of treatment.
The aims of the present study are: (1) to evaluate
the efficacy of EMDR as compared to Treatment as
Usual (TAU) in a cohort of BC patients with PTSD,
diagnosed according to DSM-5 criteria; (2) to identify
by EEG the functional changes related to EMDR
outcome; (3) to correlate such changes to those in
clinical scores.
2. Methods
2.1. Design
This was a quasi-experimental study comparing the
neurobiological correlates of two different therapeutic
interventions (EMDR and TAU) for treating cancer-
related PTSD in women with BC.
2.2. Setting
The participants were recruited at the Breast Unit
service of Città della Salute e della Scienza of Turin
between September 2016 and November 2017. The
study was approved by the local Research Ethics
Committee. Informed written consent was obtained
from all participants.
2.3. Participants
The subjects were patients with BC and a diagnosis
of cancer-related PTSD. Inclusion criteria were: (1)
diagnosis of advanced breast cancer (stage III or IV);
(2) age between 18 and 70 years; (3) diagnosis of
PTSD according to DSM-5 criteria; (4) fluent Italian
speaker; (5) legal capacity to consent to the treat-
ment; (6) willingness to suspend all concomitant
psychological treatment; (7) suspension of all psy-
chotropic medications at least one month before the
treatment or maintenance at baseline level through-
out the study.
Exclusion criteria were: (1) presence of major psy-
chiatric disorders, including severe major depression
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disorder, schizophrenia, bipolar disorder, dissociative
disorders, current abuse of alcohol or other sub-
stances; (2) inability to complete psychological assess-
ments due to visual impairment or cognitive
difficulties; (3) presence of uncontrolled symptoms
due to the medical illness or therapies.
2.4. Recruitment and measures
Proposal to participate was made by two psycholo-
gists during a clinical visit. Participants were
recruited with a three-step screening.
(1) Impact of Event Scale-Revised (IES-R) was
administered to all eligible patients fitting the
inclusion criteria and who considered only the
illness as the traumatic event. The IES-R
(Weiss & Marmar, 1997) is a 22-item self-
report questionnaire consisting of three sub-
scales: intrusion, avoidance and hyperarousal.
The scale assesses subjective distress caused by
traumatic events. A cut-off equal to or above
33 is considered indicative of posttraumatic
stress symptoms (Creamer, Bell, & Failla,
2003).
(2) Patients with scores equal to or above 33 were
assessed with the PTSD module of Structured
Clinical Interview for DSM-5 (SCID-5; First,
Williams, Karg, & Spitzer, 2015) in order to
confirm diagnosis of PTSD.
(3) Patients were assessed with the Clinician-
Administered PTSD Scale (CAPS-5; Weathers
et al., 2018), a semi-structured interview based
on the DSM-5, considered the gold standard
for diagnosing PTSD. Severity rating is calcu-
lated by combining frequency and intensity
scores. During the CAPS-5 administration,
the narrative of the worst traumatic event
related to BC history (target event) was
audio-recorded and, if patients accepted their
participation in the study, was used as script
during the EEG recordings.
The research protocol with an explanation of the
aims of the study was proposed to all consecutive
patients with confirmed PTSD diagnosis, asking
whether they were willing to receive a more intensive
psychotherapeutic intervention (EMDR) other than
TAU. On reaching the maximum number of patients
in the EMDR group, the remaining patients were
assigned to the TAU group. Upon agreement, they
signed the written informed consent and were asked
to complete the following psychological questionnaires.
Trauma Antecedent Questionnaire (TAQ;
Luxenberg, Spinazzola, & Van Der Kolk, 2001) a
self-administered instrument that gathers past infor-
mation about adverse childhood experiences and
other traumatic life experiences, assessed at four dif-
ferent age periods: early childhood (birth to six years),
latency (seven to 12 years), adolescence (13 to
18 years) and adulthood. This questionnaire was
administered only at baseline.
State-Trait Anxiety Inventory (STAI-Y;
Spielberger, 1983) used to measure the presence and
severity of current symptoms of anxiety (state anxi-
ety; STAI-1) and a generalized propensity to be
anxious (trait anxiety; STAI-2). Range of scores for
each subtest is 20–80, with the higher score indicating
greater anxiety.
Beck Depression Inventory-II (BDI-II; Beck &
Steer, 1993), a 21-item self-report instrument that
assesses the presence and severity of depression
symptoms. A score above 13 indicates presence of
depression symptoms.
Psychological assessment was performed by psy-
chologists independent of the research protocol and
blinded to treatment group, using the same timing
and tools in both groups, i.e. at baseline before the
first session of treatment (T0) and after treatment’s
end (T1).
2.5. Treatments
2.5.1. Treatment as usual
The TAU group received four sessions of supportive
therapy, one every other week over a period of two
months. They consisted of standard treatment to
support patients to better deal with the psychological
symptoms related to BC. TAU was performed by two
psychotherapists at MSc level or higher, with a mini-
mum of three years of experience in treating patients
with BC. They received supervision by an experi-
enced colleague for the duration of the study.
2.5.2. Eye movement desensitization and
reprocessing
Participants received 10 EMDR sessions over a period
that varied between two and three months. EMDR
was administered in accordance with Shapiro’s pro-
tocol for traumatic events (Shapiro, 2001) and parti-
cularly it followed the EMDR specific protocol for
oncological patients (Faretta & Borsato, 2016). In the
first two sessions patients were trained to stabilization
techniques, such as the Safe Place or mindfulness-
based practices. The remaining sessions focused on
trauma reprocessing, starting from the target event
(identified in the CAPS-5 interview and used as a
script during the EEG recording) and then moving
to other related traumatic material and events. EMDR
was provided by three practitioners with a minimum
of three years of experience in the liaison setting.
They received supervision from a certified senior
EMDR supervisor for the entire duration of the study.
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2.6. EEG data recordings
EEG was recorded by a Galileo system (EBNeuro,
Florence, Italy) with patients seated on a comfortable
chair in a quiet room. Thirty-seven active electrodes
were applied to the scalp using a pre-cabled electrode
cap. Data were collected and digitalized at a sampling
rate of 1024 Hz.
Participants were assessed using EEG at two sepa-
rate time points: at baseline (T0), all participants
received two resting state EEG measurements, with
eyes open and eyes closed and one EEG measurement
during script-driven imagery, and then two other
resting state EEG measurements, again with eyes
open and eyes closed. After the last session of
EMDR or TAU treatment (T1), the EEG resting
state (eyes open and eyes closed) and script-driven
imagery sessions were repeated.
2.7. EEG data analysis
Only the data during the listening of the script were
analysed in the EEGLAB environment (http://www.
sccn.ucsd.edu/eeglab/index.html) and a collection of
scripts running under Matlab R2014b (Mathworks
Inc., Natick, MA). All EEG signals were bandpass
filtered (1–40 Hz) since muscular artefacts were pre-
sent in the data due to the clinical condition of the
participants and average referenced was applied
before further analysis. Artefactual non-cerebral
source activities (eye blinks and movements, micro-
saccadic, cardiac and muscle/electromyographic
activity) were identified and rejected using a semiau-
tomatic procedure based on Independent Component
Analysis (Barbati, Porcaro, Zappasodi, Rossini, &
Tecchio, 2004; Porcaro, Medaglia, & Krott, 2015).
Power spectral density (PSD) was estimated for each
channel, using the Welch procedure (1024 ms dura-
tion, Hanning window and 60% overlap). We inves-
tigated the spectral properties in the classical
frequency bands, such as delta band (1–3 Hz), theta
band (4–7 Hz), alpha band (8–13 Hz) and beta band
(14–32 Hz) (IFSECN 1974).
We used an equivalent current dipole (ECD) with
four concentric conductive spheres model (see rou-
tine DIPFIT2 of EEGLAB v11.0, available at http://
www.sccn.ucsd.edu/eeglab) to obtain ECD positions
in Talairach space for delta plus theta power differ-
ence between T1 minus T0 for the EMDR group.
Talairach coordinates were transformed in Montreal
Neurological Institute (MNI) space and plotted on
MNI template using MRICro (www.mricro.com).
2.8. Statistical analyses
Data were processed and analysed using the Statistical
Package for Social Sciences (SPSS version 22.0;
Chicago, IL, USA). Both parametric and nonpara-
metric tests were used, in accordance with Shapiro–
Wilk as a test for normality. Baseline group differ-
ences were assessed using Student’s t-test or Mann–
Whitney U test to compare the two groups for con-
tinuous measures and Fisher’s Exact Test for catego-
rical measures.
Fisher’s Exact Test was used to evaluate the asso-
ciation between the treatment group (EMDR vs.
TAU) and the PTSD diagnosis at T1. Cramer’s V
was used to calculate the effect size for the proportion
of participants that no longer meet PTSD diagnosis as
measured with CAPS at T1.
A GLM repeated measures multivariate ANOVA
(RM-MANOVA) was used to analyse the main pre-
and post-intervention effects and interactions both
between and within the EMDR and TAU groups.
Pairwise comparison between groups were made by
simple contrast and are reported as means difference
with the Sidak correction 95% confidence interval
(95% CI) for multiple comparisons.
A multivariable linear regression analysis was per-
formed to determine the association between group
(EMDR vs. TAU) and each clinical outcome. Two
models for each outcome were performed: in the
first model the association between the clinical score
at T1 and treatment was adjusted only with the clin-
ical score at T0; in the second model an additional
adjustment for possible confounding variables (the
ones that resulted significant at T0, i.e. age and
CAPS-C) was carried out. To verify the goodness-
of-fitness of the models, the adjusted R2 value was
computed.
Moreover, two-sample permutation t-tests (10,000
permutations, avoiding multiple comparisons pro-
blem) among channels were performed to investigate
differences in PSD at T0 and T1 between the TAU
and EMDR groups. Pearson correlation analysis was
also performed between power bands (delta, theta,
alpha and beta) and the clinical scores. A p < .05
was considered statistically significant throughout all
of the analyses.
3. Results
A total of 567 patients with BC were screened with
IES-R; 224 presented a IES-R score above the cut-off
(39.5%). Of those, 86 were excluded on the basis of
the inclusion/exclusion criteria (38.4%). Of the
remaining 138, 73 were not available or refused to
continue the evaluation (52.9%). Only 46 met the
criteria of PTSD diagnosis (8.1% of the total) accord-
ing to CAPS interview. Later, 16 patients declined to
participate to the study (reasons given for refusal
were mainly the distance of patients’ place of resi-
dence from the hospital and the inability to attend the
intervention sessions; refusal rate: 34.8%).
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Therefore, a total of 30 patients were enrolled in the
study: 15 were assigned to EMDR and 15 to TAU. Only
one drop-out was registered in the EMDR group.
Table 1 presents at baseline (T0) the socio-demo-
graphic characteristics of these patients. There were no
significant differences in demographics between the two
groups, except for patients in the EMDR group being
slightly older than those in the TAU group (Table 1).
At T0 there were no significant differences in
clinical characteristics between the two groups, except
for patients in the EMDR group showing higher
avoidance symptoms (CAPS-C) than the TAU
group (Table 2). Patients in the EMDR group (14
out of 14, 100%) did not meet PTSD diagnostic
criteria after treatment, while all patients in the
TAU group maintained their baseline clinical
diagnosis, with a statistically significant difference
(p ≤ .001; Cramer’s V = 1.000).
A repeated-measures MANOVA was performed
on the pre- and post-intervention clinical scores com-
paring group and time effects and interactions
between group and time yielding a significant pre–
post main effect (F(9, 19) = 21.664, p < .001;
η2p = .911), and a significant interaction between
the pre–post measures and the treatment condition
(F(9, 19) = 13.504, p < .001; η2p = .865).
Significant time effects were found across both groups
for all variables except for STAI-1 and STAI-2, indicating
that themean participant scores improved fromT0 to T1
on all variables, except for anxiety symptoms (Table 2).
Group-by-time interaction effects were found for
IES-R, CAPS-TOT, CAPS-B, CAPS-C, CAPS-D,
CAPS-E and BDI-II scores, indicating that clinical
improvements regarding the related symptoms were
different in the two treatment groups. No group-by-
time interaction was found for STAI-1 and STAI-2,
confirming that no change was observed on these
measures (Table 2).
Planned post hoc analyses of simple pre–post effects
were conducted for all variables with a significant
group-by-time effect by GLM pairwise comparisons
using the Sidak adjustment for multiple comparisons.
As for posttraumatic symptoms, both groups had
an improvement in CAPS-TOT score, but the EMDR
group scored significantly lower compared to the
TAU group at post-treatment (Table 2). These results
were partially confirmed by IES-R, which showed an
improvement only in the EMDR group (Table 3).
A more in-depth evaluation of different clusters of
posttraumatic symptoms assessed with CAPS subscales
indicated that only the EMDR group had an improve-
ment in intrusive (CAPS-B), avoidance (CAPS-C) and
hyper-arousal (CAPS-E) symptoms (Table 3) scoring
significantly lower than the TAU group at T1 (Table 2).
Both groups improved in negative alterations in mood
and cognitions cluster (CAPS-D), but the EMDR group
scored significantly better compared to the TAU group at
post-treatment (Table 2).
Table 1. Demographic data of participants at baseline.
EMDR (N = 15)
Mean (SD)
TAU (N = 15)
Mean (SD) p
Age (years) 55.47 (7.64) 48.40 (9.42) .032a
TAQ
0–6 2.14 (1.30) 1.80 (1.35) .477b
7–12 1.95 (1.12) 2.28 (1.04) .505b
13–18 2.34 (0.77) 2.46 (0.33) 1.000b
Adult 2.59 (0.31) 2.55 (0.23) .715b
n (%) n (%)
Level of education .535c
Primary school 1 (6.67) 0 (0)
Low secondary school 6 (40) 3 (20)
High secondary school 6 (40) 9 (60)
University 2 (13.33) 3 (20)
Marital status .750c
Single 1 (6.67) 3 (20)
Married 9 (60) 9 (60)
Separated/divorced 4 (26.66) 3 (20)
Widowed 1 (6.67) 0 (0)
Employment status .409c
Unemployed 0 (0) 2 (13.33)
Employed 11 (73.33) 12 (80)
Pensioned 4 (26.67) 1 (6.67)
Type of cancer .598c
Primary 12 (80) 14 (93.33)
Relapse 3 (20) 1 (6.67)
EMDR = Eye Movement Desensitization and Reprocessing; TAU =
Therapy As Usual.
aPearson’s independent samples t-test.
bMann–Whitney U test.
cFisher’s exact test.
Table 2. Comparison of clinical variables for the two groups (EMDR and TAU).
Pre-treatment (T0) Post-treatment (T1) Effect Time Effect Time x Group
EMDR
(N = 14)
TAU
(N = 15) p
EMDR
(N = 14)
TAU
(N = 15) p F p η2p F p η
2
p
IES-R 49.64 (15.46) 53.27 (13.57) .507 16.21 (12.64) 48.60 (15.19) < .001 42.870 < .001 .614 24.437 < .001 .475
CAPS-TOT 33.57 (9.57) 33.13 (10.63) .908 6.43 (6.17) 27.87 (7.29) < .001 96.387 < .001 .781 43.915 < .001 .619
CAPS-B 9.36 (3.43) 9.33 (3.60) .986 1.93 (2.06) 7.67 (3.53) < .001 38.808 < .001 .590 15.575 .001 .366
CAPS-C 4.43 (1.65) 3.27 (0.70) .019 0.57 (0.76) 2.80 (1.01) < .001 88.190 < .001 .766 54.226 < .001 .668
CAPS-D 11.00 (4.26) 12.00 (4.23) .531 2.14 (2.03) 9.27 (2.96) < .001 58.544 < .001 .684 16.343 < .001 .377
CAPS-E 8.93 (3.27) 8.53 (4.50) .790 2.00 (1.66) 7.60 (2.95) < .001 36.415 < .001 .574 21.176 < .001 .440
STAI-1 40.07 (9.47) 45.13 (10.85) .193 44.71 (4.46) 44.73 (10.07) .995 1.614 .215 .056 2.280 .143 .078
STAI-2 43.64 (6.56) 44.80 (6.54) .638 45.50 (4.78) 42.33 (5.49) .110 0.066 .800 .002 3.301 .080 .109
BDI-II 23.93 (6.89) 24.80 (9.94) .787 10.50 (7.08) 24.93 (7.95) < .001 25.242 < .001 .483 21.176 < .001 .440
Data are mean (SD).
TAU = Therapy As Usual.
EMDR = Eye Movement Desensitization and Reprocessing.
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As for BDI-II, there was a significant improvement
in the EMDR group while no difference was found in
the TAU group (Table 3) and the EMDR group
scored significantly lower than the TAU group at
post-treatment (Table 2).
In order to check whether the variables that were
significantly different between groups at T0 (i.e. age
and CAPS-C) could have influenced the observed
clinical outcomes at T1, a multivariable linear regres-
sion analysis was performed. As reported in Table 4,
no evidence of confounding due to age and CAPS-C
was found. All models, except for STAI-1 and STAI-2
showed a good fit, thus confirming that being treated
with EMDR resulted in an improvement from T0 to
T1 on all variables, except for anxiety (Table 4).
3.1. Power spectral density results
3.1.1. Channels selection
We found that the permutation t-test on the PSD
among channels showed statistically significant differ-
ences (T0 vs. T1) in delta (1–3 Hz) and theta (4–7 Hz)
bands for P3 and PO8 channels, respectively, only for
patients treated with EMDR (see Figure 1).
3.1.2. Localization analysis
Localization analysis on the EMDR power difference
between T0 vs. T1 showed activations on left Angular
Gyri (left BA39 –MNI coordinates: −32; −76; 44) and
right Fusiform Gyri (right BA37 – MNI coordinates:
31; −78; 2) see Figure 2.
Table 3. Comparison between T0 and T1 of clinical variables for the two groups (EMDR and TAU).
EMDR (N = 14) TAU (N = 15)
T0 T1 Mean difference (95% CI) p T0 T1 Mean difference (95% CI) p
IES-R 49.64 (15.46) 16.21 (12.64) −33.429 (−42.014; −24.843) < .001 53.27 (13.57) 48.60 (15.19) −4.667 (−12.961; 3.628) .258
CAPS-TOT 33.57 (9.57) 6.43 (6.17) −27.143 (−32.014; −22.271) < .001 33.13 (10.63) 27.87 (7.29) −5.267 (−9.973; −.560) .030
CAPS-B 9.36 (3.43) 1.93 (2.06) −7.429 (−9.583; −5.274) < .001 9.33 (3.60) 7.67 (3.53) −1.667 (−3.748; .415) .112
CAPS-C 4.43 (1.65) 0.57 (0.76) −3.857 (−4.537; −3.178) < .001 3.27 (0.70) 2.80 (1.01) −.467 (−1.123; .190) .156
CAPS-D 11.00 (4.26) 2.14 (2.03) −8.857 (−11.093; −6.622) < .001 12.00 (4.23) 9.27 (2.96) −2.733 (−4.893; −.574) .015
CAPS-E 8.93 (3.27) 2.00 (1.66) −6.929 (−8.851; −5.006) < .001 8.53 (4.50) 7.60 (2.95) −.933 (−2.791; .924) .312
STAI-1 40.07 (9.47) 44.71 (4.46) 4.643 (−.286; 9.571) .064 45.13 (10.85) 44.73 (10.07) −.400 (−5.161; 4.361) .864
STAI-2 43.64 (6.56) 45.50 (4.78) 1.857 (−1.655; 5.369) .288 44.80 (6.54) 42.33 (5.49) −2.467 (−5.860; .926) .147
BDI-II 23.93 (6.89) 10.50 (7.08) −13.429 (−17.334; −9.524) < .001 24.80 (9.94) 24.93 (7.95) .133 (−3.639; 3.906) .943
Data are mean (SD).
TAU = Therapy As Usual.
EMDR = Eye Movement Desensitization and Reprocessing.
Table 4. Multivariable linear regression models for each clinical score at T1. β values regard the effect of receiving EMDR (vs.
TAU).
Model 1* Model 2§
Outcome (T1) β treatment (SE) p Adj R2 β treatment (SE) p Adj R2
IES-R −30.99 (4.91) < .001 0.63 −35.65 (5.56) < .001 0.64
CAPS-TOT −21.59 (2.21) < .001 0.78 −19.86 (2.54) < .001 0.79
CAPS-B −5.74 (1.03) < .001 0.52 −5.49 (1.22) < .001 0.50
CAPS-C −2.54 (0.35) < .001 0.65 −2.57 (0.37) < .001 0.64
CAPS-D −6.90 (0.91) < .001 0.70 −5.91 (0.97) < .001 0.75
CAPS-E −5.72 (0.80) < .001 0.66 −5.57 (0.95) < .001 0.64
STAI-1 2.06 (2.61) .437 0.23 1.40 (3.07) .653 0.19
STAI-2 3.55 (1.78) .057 0.19 3.48 (2.03) .099 0.21
BDI-II −13.96 (2.25) < .001 0.66 −13.09 (2.71) < .001 0.64
*adjusted by clinical score at T0.
§adjusted by clinical score at T0, age and CAPS-C.
SE = Standard Error.
Figure 1. T0 vs. T1 power spectral density analysis (PSD).
(Middle) Topographic representation of the permutation t-test for delta plus theta bands (T0 vs. T1). (Left) PSD of channel P3 for the TAU and
EMDR groups for T0 (blue line) and T1 (red line). (Right) PSD of channel P08 for the TAU and EMDR groups for T0 (blue line) and T1 (red line).
For both left and right panel solid horizontal black line (area highlighted in grey) indicate significant difference between T0 and T1 (p < .05).
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3.1.3. Correlation analysis power bands vs. clinical
scores
To understand the neural correlates of symptom
improvement following EMDR treatment, Pearson
correlation analysis was performed between delta
values of the power bands and the delta values of
the clinical score. The delta was calculated as follows:
Δ valueð Þ ¼ T1 valueð Þ  T0 valueð Þ
T0 valueð Þ
where value indicates PSD in delta, theta, alpha and beta
bands or the clinical score. We found that Δ(IES-R) and
Δ(CAPS-TOT) negatively correlated withΔ(PSDdelta) for
channel P3 (Figure 3).
Furthermore, for the same channel, Δ(IES-R)
negatively correlated with Δ(PSDtheta). Δ(CAPS-
TOT) and Δ(BDI-II) negatively correlated with Δ
(PSDdelta) for channel PO8 (Figures 2 and 3). These
results indicate that symptoms reduction was asso-
ciated with an increased PSD delta between T0 and
T1. No correlation was observed in the TAU group in
any of the PSD bands. Results from correlations indi-
cate that the higher the Δ(clinical score) (higher nega-
tive value) the higher the power increase in delta and
theta bands after EMDR.
4. Discussion
To our knowledge, this is the first study to apply
DSM-5 diagnostic criteria for assessing PTSD in
patients with cancer, and to evaluate therapy out-
comes by EEG neuroimaging. Our results show that
the prevalence of BC-related PTSD is in line with that
reported by previous studies which used DSM-IV
Figure 2. T0 vs. T1 EMDR PSD difference localization analysis.
Position of the equivalent current dipole (ECD) superimposed on the MNI brain template and Brodmann areas template (within MRICron
software – www.mricro.com) are shown. Axial, coronal, and sagittal views are shown for the Angular Gyrus (left panel) and Fusiform Gyrus
(right panel) PSD difference between T0 vs. T1 EMDR group. Talairach (x, y, z) coordinates as well as MNI coordinates and Broadman areas (BAs)
are also shown.
Figure 3. Correlation analysis.
(Upper row – left) Pearson correlation analysis between Δ(PSDdelta) channel P3 and Δ(IES TOT), Δ(CAPS TOT) and Δ(BDI). (Upper row – right)
correlation analysis between Δ(PSDtheta) same channel and Δ(IES TOT). (Lower row – left) Pearson correlation analysis between Δ(PSDdelta)
channel PO8 and Δ(IES TOT), Δ(CAPS TOT) and Δ(BDI). (Lower row – right) correlation analysis between Δ(PSDtheta) same channel and Δ(IES
TOT). Correlation R value and p value were reported on the top right corner of each panel.
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criteria (Abbey et al., 2015; Andrykowski et al., 2000;
Swartzman et al., 2017). Since DSM-5 stated that
medical illness per se could no longer be considered
as a potential traumatic event, it became a matter of
controversy whether the diagnostic category of
Adjustment Disorder (AD), rather than PTSD, better
describes cancer patients’ experiences in dealing with
their disease (Cordova et al., 2017; Kangas, 2013).
Our results show that a fifth of BC patients who
exhibit posttraumatic stress symptoms (i.e. IES score
≥ 33) met full criteria for PTSD, thereby suggesting
the appropriateness of applying the concept of PTSD
to this medical condition and limiting the AD diag-
nosis to patients exhibiting posttraumatic stress
symptoms without meeting full PTSD diagnostic cri-
teria (Kangas, 2013).
One of the factors contributing to PTSD symp-
toms in response to cancer is the presence of pre-
cancer diagnosis adverse/traumatic experiences
(Cordova et al., 2017; Green et al., 2000).
Accordingly, in our study a great majority of patients
have experienced previous adverse childhood experi-
ences or traumatic events (Table 1), suggesting that
the assessment of patients’ trauma history should be a
standard part of clinical routine, as already stated by
the National Comprehensive Cancer Network’s clin-
ical practice guidelines (2018).
Development of appropriate treatment pathways
in the oncology setting that can optimize detection
and management of cancer-related PTSD is claimed
by both clinicians and researchers (Cordova et al.,
2017). One aim of the present study was to evaluate
if EMDR was more effective than TAU in reducing
posttraumatic symptoms in women with BC-related
PTSD. As expected, EMDR was superior to TAU in
reducing the proportion of patients with a PTSD
clinical diagnosis. Only EMDR resulted in a clinically
significant improvement, reaching scores below the
clinical threshold in intrusive, avoidant and hyper-
arousal symptoms. These results are in accordance
with guidelines that indicate that trauma-focused
therapies, such as EMDR and TF-CBT, are more
effective than non-trauma focused intervention in
treating PTSD (Bisson & Andrew, 2007; National
Collaborating Centre for Mental Health, 2005).
Furthermore, in the present study, only EMDR
was found to be effective in reducing depressive
symptoms, as previously demonstrated in other
patient groups (Carletto et al., 2017; Chen et al.,
2014; Ostacoli et al., 2018).
Neither EMDR nor TAU were effective in redu-
cing anxiety symptoms, in contrast with previous
research on PTSD (Chen et al., 2014). This might be
due to the peculiar medical condition of patients with
cancer, in whom sustained anxiety could be related to
realistic concerns about the recurrence and the pro-
gression of the disease. Moreover, future oriented
fears differ from intrusive memories or re-experien-
cing of cancer-related stressors that have already
occurred (Cordova et al., 2017).
The superiority of EMDR in treating cancer-
related PTSD in women with BC was also supported
by EEG results in which the power spectral density
extracted from single channels allows us to quantita-
tively characterize neuronal changes occurring in dif-
ferent conditions. The clinical improvement in
patients following EMDR, as expressed by the scores
of psychological tests, was associated with an
increased difference (increased Δ) of the EEG power
in delta and theta bands. Such change is due either to
a higher local neuronal synchronization or to a
higher recruitment of neurons, implying better com-
munication between different brain regions.
Consequently, neuronal desynchronization or inhibi-
tion of neuronal networking might be one of the
neurobiological mechanisms underlying PTSD
symptomatology.
Locations in which such increases took place are
P3 and PO8, approximately corresponding to the left
angular (BA 39) and right fusiform gyri (BA 37),
respectively. The angular gyrus lies in correspondence
to the temporo-parieto-occipital junction (Brodmann
area 37), which has been previously described as the
brain region whose cortical electric activity was most
associated with symptom improvements following
EMDR (Pagani et al., 2012). Upon symptom disap-
pearance the posterior multisensory associative cortex
was found to fire during the reliving of the traumatic
experience. This result supports the hypothesis that
preferential brain activation shifted, after EMDR
therapy, from limbic regions with an emotional
valence to cortical regions with cognitive and seman-
tic valence.
As for changes occurring in the right fusiform
gyrus, a dysfunction of this region was found in
patients with PTSD and could be related to an altered
visual perception and sensory integration (Kennis,
van Rooij, van Den Heuvel, Kahn, & Geuze, 2016;
Mueller-Pfeiffer et al., 2013) that might explain the
difficulties that patients with PTSD have in spatial
and temporal contextualization. The restored activity
of this region after successful EMDR could facilitate
an elaboration at higher cognitive level of the images
related to the traumatic event, allowing better proces-
sing and contextualization. This finding is in accor-
dance with previous results showing an increased
right fusiform gyrus electrical activation upon trau-
matic script during the last session of successful
EMDR (Pagani et al., 2012).
Therefore, EMDR might increase the cortical con-
nections between different brain regions resulting in
a better capability to adapt the traumatic experience
into associative cortices. These results are also in
accordance with a recently proposed two-stage
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cortical coherence model (Keller, Stevens, Lui,
Murray, & Yaggie, 2014; Yaggie et al., 2015), which
hypothesizes that EMDR could facilitate the reproces-
sing of traumatic memories by increasing neural
interconnectivity. This aspect might be a target
point for future interventions to re-establish correct
neuronal functioning.
Limitations of the study are the relatively small
number of patients and the lack of random allocation
to intervention groups. This was mainly due to the
exploratory nature and the complexity of the research
design, and to the high costs of neuroimaging proce-
dure and analyses. Moreover, other limitations of the
study are related to the different treatment dose
received by patients (i.e. 10 sessions for EMDR and
four sessions for TAU) and the possible expectancy
effect (i.e. EMDR was presented as a more intensive
psychotherapeutic intervention in respect to TAU).
These difference should be taken into account when
interpreting the results, and future studies should be
designed with more balanced interventions.
Finally, another limitation of the study relates to
the nature of the EEG techniques, which tend to be
more sensitive to cortical activity rather than to activ-
ity in subcortical areas, which have also been widely
implicated in PTSD. Further studies are needed to
extend and replicate these findings.
In conclusion, the present study emphasizes the
importance of detecting PTSD symptoms in patients
with BC in order to offer them appropriate and
effective treatments. EMDR could be an ideal candi-
date to treat cancer-related PTSD and associated psy-
chological symptoms in current clinical practice as its
functional effects are supported from both a clinical
and a neurobiological point of view.
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